Genmab (GMAB) news
Recent news
Genmab: UBS raises target price to DKK 3100 from DKK 2700
AInvest Wire · 8h agoGenmab - Darzalex Q3 2026 net sales USD 2.53 bln in U.S., USD 1.71 bln rest of world
Genmab A/S (Nasdaq: GMAB) reported third-quarter 2026 net sales of DARZALEX® (daratumumab) in the United States of USD 2.53 billion, with USD 1.71 billion in sales from the rest of the world, according to data provided by Johnson & Johnson. This represents a decline in U.S. sales compared to the…
AInvest Wire · 1d agoGenmab A/S: Barclays raises target price to DKK 3100 from DKK 2900
AInvest Wire · 5d agoGenmab: Deutsche Bank raises target price to DKK 3000 from DKK 2750
Deutsche Bank has raised its price target for Genmab A/S to DKK 3,000 from DKK 2,750, while maintaining its "buy" rating . The adjustment follows recent positive developments in Genmab’s pipeline, including the first Phase 3 data for its lymphoma treatment, Epkinly, in the EPCORE-DLBCL2 trial,…
AInvest Wire · 5d agoGenmab: BofA global research raises price objective to DKK 2850 from DKK 2500
Genmab shares rose over 8% on October 8, 2026, following the company’s second-quarter results and an updated 2026 outlook. The Danish biotech firm reported first-half revenue of $2.05 billion, a 25% increase compared to $1.64 billion in the same period of 2025, driven by higher royalties from…
AInvest Wire · 6d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.